<DOC>
	<DOCNO>NCT01845350</DOCNO>
	<brief_summary>The purpose study determine whether M2 macrophage safe feasible treatment non-acute stroke patient</brief_summary>
	<brief_title>Safety Autologous M2 Macrophage Treatment Non-Acute Stroke Patients</brief_title>
	<detailed_description>Our primary hypothesis autologous M2 macrophage transplantation via intrathecal introduction feasible safe non-acute stroke . Our secondary hypothesis autologous M2 macrophage transplantation associate improved neurological outcome non-acute stroke</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Computed tomography confirm ischemic hemorrhagic stroke Duration since stroke onset 3 less 12 month Age 18 75 year old Persistent neurological deficit 4 point NIHSS stroke scale Signed inform consent The history previous stroke Seizures Thrombophilias primary hematological disease Malignancy Hepatic renal dysfunction Hemodynamic respiratory instability Autoimmune disease HIV uncontrolled bacterial , fungal , viral infection Pregnancy Participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>